We live in a world populated by an enormous number of micro-organisms. This necessitates the existence of highly effective mechanisms to control microbial growth. Through many research efforts, a chemical defense system based on the production of antimicrobial proteins (AMPs) has been identified. AMPs are endogenous, small proteins exhibiting antimicrobial activity against a wide variety of micro-organisms. The wide distribution of these molecules in the plant and animal kingdom reflects their biological significance. Various human AMPs show a potent effect on pathogenic micro-organisms including antibiotic-resistant bacteria. Thus, there is great interest in understanding the role of AMPs within innate immunity and evaluating their use and/or specific induction to fend off infections. In this review, we provide an overview of the characteristics of human AMPs and discuss examples where AMPs may be involved in the pathogenesis of infectious and inflammatory diseases.
INTRODUCTION
Antimicrobial proteins (AMPs) are endogenous, generally small proteins, which are characterized by their capacity to kill a wide variety of micro-organisms. AMPs are effector molecules of the innate immunity and offer a fast and rapid response to invading micro-organisms. The wide distribution of AMPs in plants, invertebrates and vertebrates reflects the important role of AMPs in innate immunity. 1 The Antimicrobial Sequences Database (<www.bbcm.univ.trieste.it/~tossi/pag1.htm>) and the Antimicrobial Peptide Database (<http://aps.unmc.edu/ AP/main.php>) indicate the abundance and diversity of AMPs. Organisms such as plants and invertebrates, which do not have an adaptive immune system, rely on the production of AMPs to fend off harmful microbes. It is likely that all multicellular organisms are capable of producing AMPs. Hence, it is not surprising that humans also express a huge number of various AMPs. Table 1 provides an overview of human AMPs. In this review, we shall focus on four major classes of human AMPs -defensins, cathelicidins, S100 proteins and ribonucleases. In addition, we review recent data providing evidence for a role of AMPs in the pathogenesis of infectious and inflammatory diseases and discuss the potential use of AMPs as drugs. We shall focus primarily on the role of AMPs as endogenous antibiotics. However, it should be mentioned that, in addition to their antimicrobial activity, AMPs exhibit various immunomodulatory activities such as recruitment and activation of antigen-presenting cells. 2 
ANTIMICROBIAL PROTEINS

Human neutrophil α α-defensin peptides (HNPs 1-4)
The human neutrophil α-defensins (HNP-1, HNP-2, HNP-3 and HNP-4) are small (3-4 kDa) cationic, arginine-rich peptides with a β-sheet structure and a typical cysteine backbone consisting of 6 cysteines which are connected via three disulfide bridges ( Fig. 1 ). Due to their abundance in neutrophilic granulocytes, they were termed human neutrophil defensins (HNPs). 
HNP1-HNP4 Neutrophils
Broad spectrum of antimicrobial activity 5 including antiviral activity [6] [7] [8] [9] Chemo-attracts monocytes, T-cells and dendritic cells [11] [12] [13] [14] Inhibition of complement activation 223, 224 Activation of mast cells 67 
HD-5
Intestinal tract Released as propeptide by Paneth cells and processed to the active form by trypsin 21 β β-Defensins hBD-1 Keratinocytes, airway Weak antimicrobial activity compared to other β-defensins 28 epithelia, urogenital tract Potential role as a tumor suppressor gene 37 hBD-2 Keratinocytes, airway Mainly active against Gram-negative bacteria and fungi 225 
epithelia, intestinal tract
Chemo-attracts dendritic and T-cells 35 as well as human neutrophils 65 and mast cells 66 hBD-3 Keratinocytes, airway Potent broad spectrum of antimicrobial activity 68, 69, 76, 78, Airway epithelia, Potent activity against P. aeruginosa, less activity against E. coli and keratinocytes (mRNA)
Gram-positive bacteria 82
Cathelicidin LL-37 Leukocytes, airway epithelia, Antimicrobial activity against bacteria 131 and viruses [133] [134] [135] urogenital tract, keratinocytes Processed to antimicrobial active forms by proteinase 3 128 and kallikreins 5 and 7 188 Many immunomodulatory functions 227
Ribonucleases
Eosinophil cationic Eosinophilic leukocytes Antibacterial and antiviral activity 88 protein (ECP) Eosinophil-derived Eosinophilic leukocytes Antiviral activity 88 neurotoxin (EDN)
Chemo-attracts and activates dendritic cells 94, 95 Angiogenin Leukocytes, epithelial cells, Antimicrobial activity 103 (RNase 5) fibroblasts Angiogenic activity 99, 100 Dermcidin (DCD-1) Sweat glands Anionic peptide, exclusively produced by human eccrine sweat glands 230, 231 Antileukoprotease Keratinocytes, airway Broad-spectrum antimicrobial activity 232, 233 (ALP) epithelia,gut, body fluids Inhibits various proteinases, e.g. elastase, cathepsin G and trypsin 234 Contributes to anti-HIV effect of saliva 235, 236 Lysozyme Skin, airway epithelia, Exhibits muramidase-dependent and muramidase-independent antibacterial body fluids activity 237 Elafin Neutrophils, epithelial cells Weak antimicrobial activity Potent inhibitor of elastase 238, 239 and proteinase 3 240 Phospholipase A 2 Neutrophils, macrophages, Active especially against Gram-positive bacteria 241 (PLA 2 )
Paneth cells, tears Killing mechanism involves phospholipid hydrolysis of the bacterial peptidoglycan 241 Peptidoglycan Neutrophils, various Antibacterial activity depends on interaction with cell wall recognition proteins epithelial cells peptidoglycan 242, 243 
Neutrophil gelatinase-Neutrophils, various Exhibits bacteriostatic activity through its ability to bind bacterial ferric associated lipocalin epithelial cells siderophores 154 (NGAL)
Hepcidin
Liver Mainly acts as an iron-regulatory hormone 244, 245 Probably limits iron availability to invading micro-organisms 244
HNPs 1-3
HNPs 1-3 were originally purified from normal human neutrophils. 3, 4 They constitute more than 30% of the protein content of primary (azurophil) granules in neutrophils and exhibit a wide spectrum of antimicrobial activity against various bacteria, fungi and viruses. 5 The amino acid sequences of HNP-1, HNP-2 and HNP-3 are identical except for a single amino-terminal amino acid ( Fig. 1 ). 5 The antimicrobial characteristics of HNPs 1-3 and their abundance in neutrophils indicate that these antimicrobial peptides participate in the non-oxidative killing of phagocytosed bacteria in neutrophils. The capacity of HNPs to inactivate various viruses (e.g. human immunodeficiency virus, herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and influenza virus) suggests that these molecules may help to protect the host from virus infections. [6] [7] [8] [9] Recently, it has been demonstrated that HNPs 1-3 display antitoxic properties by inhibiting the activity of the lethal toxin of Bacillus anthracis. 10 HNPs also connect innate immunity with adaptive immunity through their capacity to chemo-attract monocytes, T-cells and dendritic cells. [11] [12] [13] [14] In addition, HNPs have potent immuno-adjuvant effects in mice by inducing the production of lymphokines, which promote T-cell dependent cellular immunity and antigen-specific immunoglobulin production. 15 
HNP-4
HNP-4 was also isolated from extracts of neutrophils and, like HNPs 1-3, it is expressed in the primary (azurophil) granules of neutrophils. 16, 17 Although HNP-4 contains the typical α-defensin cysteine backbone ( Fig. 1 ), it differs from HNPs 1-3 in its overall sequence and amino acid composition. Compared to HNPs 1-3, HNP-4 is less abundant in neutrophils (less than 1% of the total protein) but it was found to exhibit higher antimicrobial activity against Escherichia coli, Streptococcus faecalis and Candida albicans. 16 Another report demonstrated that HNP-4, in comparison with HNPs 1-3, exhibited higher activity against E. coli but lower activity against Staphylococcus aureus. 18 Structural differences between HNP-1, HNP-2, HNP-3 and HNP-4 are presumably responsible for the striking differences observed in antimicrobial activity. It has also been reported that HNP-4 exhibits antiviral activity against HIV. Furthermore, HNP-4 proved more effective than HNPs 1-3 in protecting human peripheral blood mononuclear cells from infection by both X4 and R5 HIV-1 strains. 19 α-Defensins HD-5 and HD-6
Two members of the human α-defensin family (human defensin-5 and human defensin-6 [HD-5 and HD-6]) are mainly expressed in the intestinal Paneth cells, specialized secretory epithelial cells located at the base of the small intestinal crypts. 20 HD-5 is stored in secretory vesicles as a propeptide which is cleaved by trypsin to its active form. 21 HD-5 displays potent antibacterial activity and provides protection from enteric infection. 18, 22 The most compelling evidence for the role of HD-5 in the defense against bacterial pathogens is evident from studies of mice transgenic for HD-5. These animals are completely resistant to infection and systemic disease from orally administered Salmonella typhimurium. 23
Human β β-defensins
Like the α-defensins, the β-defensins are small (4-5 kDa) cationic peptides, which possess high antimicrobial activity against a broad spectrum of micro-organisms. They differ from the α-defensins by the spacing between the cysteine residues and the topology of the disulfide bridges ( Fig. 2 ). β-Defensins typically have a short helical segment preceding a three-stranded antiparallel β-sheet. 24 Human β-defensin-1 (hBD-1)
The first discovered human β-defensin, hBD-1, was initially isolated from hemofiltrates and later found in urine. 25 Like the other β-defensins, hBD-1 is a small (36 amino acid residues) cationic peptide containing six cysteines forming three intramolecular disulfide bonds (Fig. 2) . In blood plasma and urine, several forms of hBD-1 have been isolated ranging in length from 36 to 47 amino acid residues and differing from each other by amino terminal truncation. 25 hBD-1 can also be found in mammary gland epithelia and breast milk. 26 Several reports indicate that hBD-1 is produced and secreted at microbicidal concentrations from epithelia of the genito-urinary tract. 25, 27, 28 Constitutive hBD-1 mRNA expression was detected in a number of epithelial tissues including human skin, 29, 30 the respiratory tract 31 and the oral cavity. [32] [33] [34] Recombinant and natural forms of hBD-1 (36, 39, and 42 amino acids) exhibit salt-sensitive antimicrobial activity against various laboratory and clinical strains of E. coli at micromolar concentrations (0.3-10 µM). The 36 amino acid form was found to retain antimicrobial activity even in normal urine. 25 In addition to its activity against E. coli, Singh et al. 31 reported that concentrations of 1-10 µg/ml of an hBD-1 preparation derived from a recombinant baculovirus killed Pseudomonas aeruginosa. The dose required to kill 50% of P. aeruginosa was found to be 1 µg/ml and 100 ng/ml for hBD-1 and hBD-2, respectively. 31 In other studies, only minor antimicrobial activity of native hBD-1 was detected, resulting in the killing of only a few micro-organisms. 28 As yet, no studies have reported activity of hBD-1 against pathogenic Grampositive bacteria such as Staph. aureus. Like hBD-2, hBD-1 exhibits chemotactic activity for cells stably transfected with the CC-chemokine receptor-6 (CCR6). As CCR6 is preferentially expressed by immature dendritic cells and memory T-cells, these data suggest that hBD-1 and hBD-2 may function, through interaction with CCR6, to recruit immature dendritic cells and memory T-cells to cutaneous sites of microbial invasion. 35 Recently, cancer-specific loss of hBD-1 has been found in 90% of renal clear cell carcinomas and in 82% of prostate cancers; 36 in addition, hBD-1 has been identified as a potential tumor suppressor gene in urological cancers. hBD-1 peptide inhibits bladder cancer cell proliferation and its overexpression in renal cancer cells results in caspase-3-mediated apoptosis. Promoter point mutations may be responsible for cancer-specific loss of hBD-1 expression. 37 Human β-defensin 2 (hBD-2) Human β-defensin-2 (hBD-2) was originally isolated from psoriatic scales as the first human inducible skinderived peptide antibiotic. 38 hBD-2 is a cationic, small (43 amino acid residues) AMP and has the typical βdefensin structure of a cationic peptide with six cysteines forming three intramolecular disulfide bonds (Fig. 2 ). The expression of hBD-2 in keratinocytes is induced by pro-inflammatory cytokines (i.e. TNF-α, IL-1β) and bacteria [38] [39] [40] and increased gene expression could be detected in inflamed skin. 41, 42 Recently, IL-17 and IL-22 have been identified as potent inducers of hBD-2 expression. 43, 44 The hBD-2 promoter contains putative transcription factor binding sites for nuclear factor κ-B (NF-κB) and activator protein 1 (AP-1) which mediate induction of hBD-2 by bacteria, LPS and pro-inflammatory cytokines such as IL-1 and IL-17. [44] [45] [46] [47] [48] [49] [50] [51] [52] Interestingly, a recent study indicated that keratinocytes can discriminate between commensal and pathogenic bacteria. Induction of hBD-2 in foreskin-derived keratinocytes by the skin commensal Staphylococcus epidermidis was suppressed by inhibitors of the JNK and p38 pathways, whereas induction by the skin pathogen Streptococcus pyogenes was blocked by inhibitors of NF-κB. 53 Expression of hBD-2 in chondrocytes and articular cartilage revealed that β-defensins participate in the protection of mesenchymal surfaces. 54 Natural hBD-2 shows specific antimicrobial activity against Gram-negative bacteria such as P. aeruginosa and E. coli. High concentrations (100 µg/ml) achieve bacteriostatic effects on Staph. aureus. 38 Similar to natural hBD-2, recombinant hBD-2 generated in insect cells exhibits broad spectrum antimicrobial activity against skin-relevant micro-organisms like P. aeruginosa, Staph. epidermidis and C. albicans, but only bacteriostatic activity against Staph. aureus. 40 The antimicrobial activity depends on ion composition and is sensitive to increasing concentrations of NaCl. 31, [55] [56] [57] Surprisingly, some bacteria (e.g. Burkholderia cepacia) are resistant to hBD-2. 58 Most likely, alteration of the bacterial membrane structure is important. It has been suggested, that the spirochete Treponema denticola is resistant to hBD-2 because it lacks LPS in the membrane. 59 However, other reasons would also be relevant: Group A streptococci (GAS) which produce streptococcal inhibitor of complement (SIC) show decreased susceptibility towards a number of cationic antimicrobial peptides including hBD-2 by binding of SIC towards AMPs. 60 The capacity of hBD-2 to kill bacteria in vivo has been demonstrated in a mouse gene therapy study with hBD-2-transfected Human antimicrobial proteins -effectors of innate immunity 321 tumor cells. In this study, hBD-2-bearing tumors were associated with fewer viable bacteria than controls following bacterial infection. 61 Further observations indicate that hBD-2 also plays a role in antiviral defense. Human rhinovirus (HRV) induces the expression of hBD-2 although it shows no direct antiviral activity against HRV. 62, 63 Both, hBD-2 and hBD-3 have been shown to inhibit HIV-1 replication. 64 Beside its direct microbicidal effect, hBD-2 exhibits many other immunomodulatory activities. hBD-2 recruits dendritic and T-cells to the site of microbial invasion through interaction with CCR6. 35 Furthermore, hBD-2 chemo-attracts TNF-α treated human neutrophils 65 and mast cells. 66 It also stimulates histamine release from mast cells and induces prostaglandin D synthesis, suggesting a role in the recruitment of mast cells to inflammation foci and in the modulation of proinflammatory mast cell functions. 67 Human β-defensin-3 (hBD-3) Natural hBD-3 peptide was first isolated from lesional psoriatic scales and the corresponding cDNA cloned from keratinocytes. 68 In two other studies, hBD-3 was cloned based on bioinformatics and functional genomic analysis. 69, 70 The cDNA sequence of hBD-3 encodes for a 67 amino acid peptide precursor that contains a 22 amino acid signal peptide. Native hBD-3 shares the typical β-defensin six cysteine motif ( Fig. 2 ). [68] [69] [70] hBD-3 is expressed in epithelia of many organs and in some nonepithelial tissues. Skin, gingival keratinocytes, tonsils, esophagus, trachea, placenta, adult heart, skeletal muscle and fetal thymus comprise the major hBD-3 mRNAexpressing tissues. [68] [69] [70] Expression of hBD-3 in epithelial cells is induced upon contact with bacteria. 30, 68, 71 In contrast to hBD-2, a major hBD-3 inducing cytokine is INF-γ. 30, 69, 72 Recently, activation of the epidermal growth factor receptor has been linked with induction of hBD-3 expression. 73, 74 hBD-3 is a very potent antimicrobial peptide exhibiting a broad range of activity against various potentially pathogenic bacteria and fungi including multiresistant Staph. aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). 68, 69, [75] [76] [77] [78] In addition, recent studies indicate a potential role of hBD-3 in antiviral immunity. It has been reported that hBD-3 is able to inhibit herpes simplex virus (HSV) binding and entry and blocks HIV-1 replication. 64, 79 The antimicrobial activity of hBD-3 seems to be independent of disulfide connectivity. By contrast, hBD-3-mediated chemotaxis of monocytes and CCR6-transfected HEK 293 cells strongly depends on the topology of disulfide connectivities in hBD-3. 80 Very recently, it has been reported that hBD-3 and hBD-4 are able to recruit and activate mast cells and increase skin vascular permeability in the present of mast cells. 81 Human β-defensin-4 (hBD-4) The fourth member of the human β-defensin family, hBD-4, was initially discovered by screening the human genome database. 82 Synthetic hBD-4 revealed antimicrobial activity at micromolar concentrations against P. aeruginosa and S. carnosus and hBD-4 gene expression was up-regulated by bacteria and lipopolysaccharide in respiratory epithelial cells. 82, 83 These data suggest a role of hBD-4 in the innate epithelial defense system against bacteria. Inducible gene expression of hBD-4 was also detected in primary keratinocytes, 30 but so far nothing is known about the expression of hBD-4 peptide in human skin. Gene expression of hBD-4 was also detected in intestinal epithelial cells. 84 As hBD-4 peptide has not yet been isolated in natural form and no data are available providing information about hBD-4 concentrations, the biological role of hBD-4 in innate immunity remains to be elucidated.
Human epididymis-specific β-defensins
Two novel epididymis-specific β-defensins, hBD-5 and hBD-6, have been identified by searching the human genomic database. RT-PCR revealed that hBD-5 and hBD-6 were specifically expressed in the human epididymis. 85 As yet, it is not known whether hBD-5 and hBD-6 exhibit antimicrobial activity. The epididymal sperm-binding protein ESC42 has been identified as a member of the human β-defensin family (DEFB118). Its antimicrobial activity against E. coli suggests a role in innate immunity of the reproductive tract. 86 Other human β-defensins Using a computational search strategy, Schutte and colleagues 87 identified 28 new human and 43 new mouse βdefensin genes in five chromosomal regions. Analysis of the translation frames in the EST database indicates that many of these predicted genes are transcribed. However, this remains to be experimentally proven.
Antimicrobial members of the ribonuclease (RNase) A superfamily
Members of the RNase A superfamily are characterized by homology with bovine ribonuclease A. They share a conserved structure of six or eight cysteines linked by disulfide bonds, two histidines and one lysine forming the catalytic site. 88 To date, eight human members (RNases 1-8) of the RNase A superfamily have been described. Moreover, five additional genes in the human genome that are related to the RNase A ribonucleases have been identified (RNases 9-13). 88 A common feature of the ribonucleases is their ability to degrade RNA, which is required for such physiological functions as antiviral or angiogenic activity (see below). Since
RNases are also capable of degrading human RNA in vitro, an interesting possibility is that they also play a role in degrading host-derived RNA. However, this remains to be proven. In the following section, we describe the human RNase A superfamily members which have been reported to exhibit antimicrobial activity and thus may be involved in host defense.
Eosinophil cationic protein (RNase 3)
Eosinophil cationic protein (ECP) is a major secretory protein found in eosinophilic leukocytes and in neutrophils. [89] [90] [91] ECP exhibits antibacterial activity in vitro against Gram-negative and Gram-positive bacteria. Of note, the antibacterial activity of ECP against E. coli is independent of its ribonuclease activity. 92 In contrast, antiviral activity of ECP against respiratory syncytial virus (RSV) required functional ribonuclease activity. 93 The activity against RSV suggests that ECP contributes to host antiviral defense.
Eosinophil-derived neurotoxin (RNase 2)
The name eosinophil-derived neurotoxin (EDN) derives from the neurotoxic activity of EDN when injected into the central nervous system of experimental animals. 94, 95 EDN is highly homologous (70%) to ECP and also a major constituent of eosinophilic leukocytes but has also been identified in neutrophils. 89, 91 So far, the physiological role of EDN has not been discovered. In contrast to ECP, EDN is ineffective against bacteria, but exhibits ribonuclease-dependent antiviral activity against RSV. 96 Recently, it has been demonstrated that eosinophils can protect against RSV infection in vivo. 97 The potent antiviral activity of EDN and ECP together with their abundance in eosinophils suggest that they contribute to eosinophil-mediated clearance of RSV probably by degrading viral RNA. 97 As reported for ECP, the antiviral activity of EDN requires functional ribonuclease activity. More recently, it has been shown that EDN has chemotactic and activating effects on human dendritic cells. This indicates a participation of EDN in inflammatory and immune responses. 94, 95 Angiogenin (RNase 5)
More than 20 years ago, RNase 5 was isolated as an angiogenic protein from supernatants of human carcinoma cells and was termed angiogenin. 98 Angiogenin promotes neovascularization and has been associated with tumor growth. 99, 100 The ribonucleolytic activity of angiogenin is relatively weak, but, nonetheless, seems to be essential for angiogenicity. 101 Angiogenin commonly circulates at high levels in human serum and can be detected in normal epithelial cells, fibroblasts and peripheral blood cells. 102 Hooper and colleagues 103 identified human and mouse angiogenins as novel antimicrobial proteins. They demonstrate that human angiogenin exhibits microbicidal activity at low micromolar concentrations against Strep. pneumoniae and the yeast C. albicans suggesting that angiogenin contributes to systemic responses to infection.
RNase 7
RNase 7 has been isolated from human skin extracts and cloned from keratinocytes. 104 Zhang et al. 105 isolated the RNase 7 gene by a genomic database search. RNase 7 is abundant in skin and exhibits a broad spectrum of antimicrobial activity. It is active against bacteria (including multiresistant strains) and fungi in nanomolar concentrations. This high antimicrobial activity indicates an important role of RNase 7 in cutaneous defense. 104 This hypothesis is strengthen by the fact that RNase 7 expression in keratinocytes can be induced by bacteria. 104 Very recently, it has been reported that the antibacterial activity of RNase 7 against P. aeruginosa does not require ribonuclease activity. 106 Therefore, one can speculate that the ribonuclease activity of RNase 7 contributes to other, as yet unknown, biological functions of RNase 7 (e.g. antiviral activity).
RNase 8
Recently, a novel member of the RNase A superfamily, termed RNase 8, has been discovered by searching the human genome databases. Expression of RNase 8 was detected in the placenta. 107 Interestingly, RNase 8 and RNase 7 have an amino acid sequence similarity of 78% and a genomic distance of only 15,000 bp, suggesting that their genes may have evolved from a common ancestor gene by a duplication event. 107 Recombinant RNase 8 exhibits broad-spectrum microbicidal activity in vitro against potential pathogenic micro-organisms including multidrug-resistant strains at micro-to nanomolar concentrations. 108 This suggests that RNase 8 may also contribute to the innate host defense.
S100 proteins
The S100 proteins (so named for solubility in saturated ammonium) comprise a multigene family of 21 low molecular weight (9-13 kDa) proteins which are characterized by the presence of two calcium-binding EF-hand motifs. They mediate a variety of functions in eukaryotic cells such as differentiation, cell cycle progression, intracellular Ca 2+ signaling, cytoskeletal membrane interactions and they also play a role in leukocyte chemotaxis. 109, 110 Psoriasin (S100A7)
Psoriasin was originally discovered in psoriatic skin lesions by a proteomics strategy as a new Ca 2+ -binding S100 protein of unknown biological function. 111 Recently, we have identified psoriasin as an E. coli killing factor, protecting healthy human skin from colonization with this gut bacterium. 112 Psoriasin is the dominating antimicrobial protein of human skin and it shows antimicrobial activity in vitro preferentially against E. coli at low micromolar concentrations. 112, 113 Its activity is inhibited by pretreatment of psoriasin with Zn 2+ , suggesting that its antimicrobial activity is mediated by deprivation of the essential trace element zinc. In healthy volunteers, a neutralizing psoriasin antibody increases growth of E. coli on the skin documenting that psoriasin acts as a principal bactericidal component of human skin. 112 Studies using chemically synthesized psoriasin confirmed the E. coli bactericidal action of natural psoriasin 114 and it was shown that a recombinant His-tag-psoriasin fusion protein adheres to E. coli and reduces survival. 115 Mutation of the conserved carboxyl-terminal EF-hand calcium-binding motif or heat denaturation only slightly reduced antibacterial activity of this recombinant psoriasin. Interestingly, the central region of psoriasin, including only amino acids , was demonstrated to be sufficient for full antibacterial activity. 115 Together, these data indicate that psoriasin is key to cutaneous resistance against E. coli. 116 Calprotectin (S100A8/A9) A calcium-and zinc-binding heterodimeric complex of the two S100 proteins S100A8/A9 (MRP8 and MRP14, calgranulin A and B), also known as calprotectin or calgranulin, exhibits selective biostatic activity at high concentrations against C. albicans. 117, 118 Calprotectin is abundant in neutrophils and also expressed in monocytes, macrophages and keratinocytes. 119 The mechanism of antimicrobial action of calprotectin appears to be related to competition for zinc, a growth requirement for many microbial species. 117, 120, 121 Recently, it has been shown that a calcium-dependent tetramer formation of S100A8 and S100A9 is an essential prerequisite for biological function. 122 However, future investigations are necessary to reveal whether tetramer formation is also required for antimicrobial activity.
Calcitermin
Calcitermin is a short C-terminal peptide fragment of calgranulin (S100A12), a minor calgranulin in neutrophils. Calcitermin displays bactericidal activity against Gram-negative bacteria. In contrast to psoriasin and calprotectin, zinc-binding increases the antimicrobial activity of calcitermin. 123
Cathelicidins (LL-37/hCAP-18)
Another major class of AMPs in mammals are the cathelicidins. 124, 125 Cathelicidins contain a N-terminal cathelin domain and an antimicrobial C-terminal domain. Humans have only one cathelicidin gene. 126, 127 Its product, hCAP18, is present in the secondary (specific) granules of neutrophils, and its C-terminal antimicrobial peptide, LL-37, is released as one of the major constituents through cleavage by proteinase 3. 128 LL-37/hCAP18 is expressed by many cells, including epididymis, spermatids, various lymphocytes and epithelia such as the intestine and the skin. 129, 130 LL-37 exhibits antimicrobial activity against a wide spectrum of Gram-positive and Gram-negative bacteria. 131 Although it has been demonstrated that the antimicrobial activity of LL-37 is inhibited in vitro under physiologically relevant salt and peptide concentrations, a recent report has shown that carbonate imparts to LL-37 the ability to kill at higher salt concentrations. 132 LL-37 also displays activity against various viruses such as herpes simplex virus (HSV), adenovirus and vaccinia virus. [133] [134] [135] Expression of LL-37 in colon epithelial cells can be induced by butyrate; 136 in a rabbit model, it has been demonstrated that oral butyrate treatment in shigellosis induced the cathelicidin CAP-18 (the rabbit homolog of LL-37) thereby promoting elimination of Shigella spp. 137 It has also been shown that 1,25-dihydroxyvitamin D 3 is a direct inducer of LL-37 gene expression. 138, 139 In contrast to β-defensins, LL-37/hCAP-18 is chemotactic for neutrophils, eosinophils, monocytes, and Tcells in the micromolar range, but not for dendritic cells. The chemotactic activity of LL-37 is mediated by formyl peptide receptor-like 1. 140, 141 Besides its direct antimicrobial and chemotactic function, LL-37 has also multiple roles as mediator of inflammation influencing diverse processes such as cell proliferation and migration, immune modulation, wound healing, angiogenesis and the release of cytokines and histamine. 142, 143 The in vivo role of cathelicidins in innate immunity has been demonstrated in a knockout mouse model. Mice deficient in CRAMPs (cathelicidin related AMPs, the mouse homolog to the human LL-37) were more susceptible to skin infections caused by group A streptococci (GAS) and GAS mutants resistant to CRAMPs caused more severe skin infections in normal mice. 144 Using the CRAMPs-deficient mouse model, it has also been demonstrated that CRAMPs/LL-37 plays a role in preventing urinary tract infections caused by E. coli. 145
MECHANISMS OF ACTION
The killing mechanism of AMPs is best understood for bacterial targets. To kill a microbe, the AMP has first to be attracted by the micro-organism. This is mediated by the cationic charge of most AMPs, which provides a high affinity to the negatively charged bacterial surface. 146 Cationicity has likely been conserved in AMPs as it may be essential for their initial electrostatic attraction to the electronegative cell envelopes and phospholipid membranes of bacteria and fungi. Bacterial cell surfaces have many anionic components, including lipopolysaccharide (LPS) and anionic lipids of Gramnegative bacteria, as well as teichoic and teichuronic acids of Gram-positive bacteria. Similarly, phosphomannans or related constituents often create negatively charged fungal surfaces. 147 In contrast, the outer leaflet of the membranes of higher eukaryotes is composed principally of lipids with no net charge and the presence of cholesterol reduces the activity of AMPs due either to stabilization of the lipid bilayer or to interactions between cholesterol and the peptide. 148 Although our knowledge about the exact killing mechanism of AMPs is still emerging, many studies have suggested that the bacterial membrane is the primary target for most cationic AMPs. The general proposed initial mode of action of cationic AMPs, such as the defensins and cathelicidin, is electrostatic binding of the cationic peptide to the outer, negatively charged surface of the bacteria, followed by penetration of the AMPs into the cytoplasmic membrane. [149] [150] [151] This, in turn, results in loss of membrane integrity, leakage of the intracellular cell contents and eventually lysis of the microbe. 151 The membrane insertion of AMPs is likely mediated by their amphipathic structure. 150 Many models have been proposed to explain the membrane permeabilization of AMPs. All these models have in common the formation of membrane lesions by AMPs through, for example, well-structured pores or disruption of the bilayer in a detergent-like manner, eventually leading to the formation of micelles and transient holes. 150, 151 However, because all the proposed models are mainly based on in vitro studies using model membranes, it is still not clear if the proposed models completely reflect what occurs in vivo. [150] [151] [152] In addition to membrane permeabilization by AMPs as a principal killing mechanism, many reports have described other potential killing mechanisms. 151 Examples are: (i) the induction of the non-lytic loss of ATP from actively respiring fungal cells by histatins; 153 (ii) the capability of neutrophil gelatinase-associated lipocalin (NGAL, lipocalin) to inhibit the siderophoremediated iron uptake by bacteria through its ability to bind bacterial ferric siderophores; 154 (iii) the binding of lactoferrin to free iron; 155 and (iv) the psoriasin-mediated deprivation of the essential trace element zinc. 112 Other studies have suggested that some cationic AMPs can bind to the relatively strong negative charge of nucleic acids and interfere with DNA and RNA metabolism, 150 although it is not clear whether this mechanism is used by human AMPs.
ASSOCIATED DISEASES
A role for AMPs in the pathogenesis of human disease is emerging. One interesting hypothesis is that the pathogenesis of certain infectious and inflammatory diseases involves a compromise in the function of AMPs. Indeed, there is increasing evidence that the inability of AMPs to kill micro-organisms efficiently or the deficiency of AMPs plays a role in certain diseases. Examples of such diseases are highlighted below.
Crohn's disease
Crohn's disease is a chronic inflammatory disease of the intestinal mucosa and affects, most commonly, the ileum of the small intestine and the colon. The etiology of Crohn's disease is still not understood and many hypotheses favor a potential dysregulation of T-cell mediated mucosal immunity. 156 There is increasing evidence that Crohn's disease is caused by a defect in the barrier function of the intestinal mucosa in genetically susceptible individuals. 157 In several mice models of experimentally induced colitis, the colitis does not develop when mice are kept in a germ-free environment. 156 These observations suggest that a deficiency in the control of the intestinal flora plays a major role in Crohn's disease. An interesting novel hypothesis is that the disturbed mucosal barrier is caused by a primary defect in the chemical barrier provided by intestinal AMPs. 158 These AMPs usually control the normal endogenous flora and protect the normal mucosa efficiently against adherent or entering microbes. 20, 23, 158, 159 Although our understanding of the role of AMPs in Crohn's disease needs further investigation, several studies have been conducted that support the hypothesis that a reduced expression of intestinal AMPs may contribute to the development of Crohn's disease as outlined below.
The inducible β-defensins hBD-2, hBD-3 and hBD-4 show reduced levels of induction in Crohn's disease as compared to that in ulcerative colitis. 84, 160, 161 It has been speculated that the diminished induction of inducible βdefensins in Crohn's disease may cause a defect in the intestinal epithelial barrier function that predisposes to bacterial invasion. 161 A plausible reason for the reduced β-defensin expression seen in patients with Crohn's disease might be that these patients carry low β-defensin gene copy numbers. It is known that the α -and βdefensin gene clusters on chromosome 8 have gene copy number polymorphisms. 162, 163 Gene expression studies also revealed a correlation between the genomic copy number and the expression level of β-defensins, suggesting that the defensin copy number polymorphism influences innate immunity. 162 Indeed, it has been shown recently that a low human β-defensin-2 gene copy number predisposes to Crohn's disease of the colon. 164 As mentioned above, the α-defensins HD-5 and HD-6 are exclusively produced in Paneth cells. 20 Crohn's disease patients with ileal involvement are characterized by a diminished expression of the ileal Paneth cell α-defensins HD-5 and HD-6. 165, 166 Reduced expression of intestinal Paneth cell-derived α-defensins correlates with decreased antimicrobial activity in the ileal mucosa. 166 The decrease in α-defensin expression in Paneth cells is even more pronounced in Crohn's disease patients with a mutation in the NOD2 (nucleotide-binding oligomerization domain 2) gene, which is associated with Crohn's disease and ileal involvement. 165, 166 NOD2 acts as an intracellular peptidoglycan receptor and is expressed in Paneth cells 167, 168 and other epithelial cells where it mediates the expression of defensins. 49, 169 NOD2-deficient mice also show an impaired production of Paneth cell α-defensins (cryptdins) and a higher susceptibility to oral bacterial infection. 170 The functional consequence of reduced α-defensin expression levels was examined in a transgenic mouse model, where changes in HD5 expression levels, comparable to those observed in Crohn's disease, had a significant impact on the luminal microbial flora. 166 Thus, a disturbance in antimicrobial defense, as provided by Paneth cells of the small intestine, seems to be a critical factor in the pathogenesis of ileal Crohn's disease.
Recently, Wehkamp et al. 171 provided an additional potential molecular mechanism for the Paneth cell αdefensin deficiency seen in ileal Crohn's disease. They reported that, in ileal Crohn's disease, there was reduced expression of the Wnt-signaling pathway transcription factor Tcf-4, a known regulator of Paneth cell differentiation and α-defensin expression. 171 Crohn's disease patients with ileal disease showed a consistent decrease in Tcf-4 levels and activity and a Tcf-4 dependent decrease of Paneth cell α-defensins in ileal Crohn's disease. These findings were further supported by the observation that reduced expression of Tcf-4 in heterozygous (+/-) mice was sufficient to cause a significant decrease in both Paneth cell α-defensin levels and bacterial killing activity. Based on these data, the authors hypothesized that a decrease in the Wnt signaling transcription factor Tcf-4 causes a reduction of Paneth cell α-defensins in ileal CD leading to changes in the luminal and/or surface bacteria composition, which, in turn, triggers inflammation in Crohn's disease. 171 Further studies are necessary to prove this interesting hypothesis and to elucidate whether genetic variants in the Tcf-4 gene or Tcf-4 regulatory pathway predispose to the development of Crohn's disease.
In addition to the defensins, it was recently demonstrated that the antimicrobial serine antiproteases elafin and secretory leukocyte protease inhibitor (SLPI) 326 Harder, Gläser, Schröder showed enhanced expression in inflamed versus noninflamed ulcerative colitis and this induction was significantly attenuated in Crohn's disease. 172 Also, the colonic expression of the human cathelicidin hCAP-18/LL-37 was increased in inflamed and non-inflamed mucosa in patients suffering from ulcerative colitis, but not in Crohn's disease. This deficiency may further compromise the antimicrobial barrier in Crohn's disease. 173 A recent study detected reduced antimicrobial activity of the colonic epithelium in Crohn's disease. 174 This is consistent with the reported low AMP expression in Crohn's disease and further strengthens the hypothesis that an AMP deficiency may promote a host-microbe imbalance at the intestinal mucosa leading to infection and inflammation as seen in patients with Crohn's disease ( Fig. 3 ). 175 However, future research is needed to evaluate the role of AMPs in Crohn's disease further.
Cystic fibrosis
Cystic fibrosis is a life-threatening inheritable disease caused by mutant cystic fibrosis transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate regulated chloride channel. 176, 177 Patients with cystic fibrosis have a predisposition to subsequent chronic bacterial infection leading to progressive lung destruction. It has been postulated that the activity of antimicrobial molecules is compromised by changes in the composition of the airway surface liquid in lungs of cystic fibrosis patients. 178 According to the 'high salt hypothesis', the high salt concentration in cystic fibrosis airway fluid caused by the lack of functional chloride channels inhibits salt-sensitive antimicrobial peptides, such as the defensins from killing bacteria. 179 Inactivation of the antimicrobial activity of AMPs leads to bacterial colonization of the lung and increased susceptibility to lung infections (Fig. 4) . 178, 179 However, other reports found no change in the salt composition in the airway surface fluid of cystic fibrosis patients. 180 Other studies suggested alternative models such as increased binding of cystic fibrosis airway epithelial cells to bacteria, a defect in bacterial internalization, or hyperabsorption of fluid by the airway surface epithelium leading to thickened airway secretions. 179 It is unclear which of these proposed mechanisms are important in vivo and whether or not they act in combination. 179 It has also been demonstrated that hBD-2 and hBD-3 are susceptible to degradation and inactivation by the cysteine proteases cathepsins B, L, and S. 181 These three cathepsins are present and active in broncho-alveolar lavages from cystic fibrosis patients and incubation of hBD-2 and hBD-3 with broncho-alveolar lavages from cystic fibrosis patients leads to the degradation of these antimicrobial molecules. In this study, the authors speculated that, in cystic fibrosis, overexpression of cathepsins may lead to increased degradation of hBD-2 and hBD-3, thereby favoring bacterial infection and colonization.
In another study, overexpression of the cathelicidin LL-37 in cystic fibrosis xenografts was shown to increase the antimicrobial activity of airway surface fluid and restored bacterial killing. This study demon-Human antimicrobial proteins -effectors of innate immunity 327 strated an alternative genetic approach for the treatment of cystic fibrosis based on enhanced expression of an endogenous antimicrobial peptide. 182
Skin diseases
Psoriatic skin is characterized by a high expression of various AMPs which may be a result of local induction through micro-organisms and endogenous pro-inflammatory cytokines. 113 The abundance of AMPs in psoriatic skin offers an explanation as to why patients with psoriasis suffer fewer cutaneous bacterial infections than expected. 183 In contrast, induction of AMPs, such as β-defensins and LL-37, seems to be reduced in the common chronic inflammatory disease atopic dermatitis. 72, 184, 185 It has been assumed that the induction of AMP expression in inflamed atopic lesions is inhibited by elevated T-helper lymphocyte type 2 (TH 2 ) cytokines found in atopic skin. Indeed it has been shown that TH 2 cytokines like interleukin (IL)-4, IL-10 and IL-13 suppress the cytokine-mediated induction of AMPs. 72, 185, 186 Another reason for the reduced induction of AMPs may be the lack of major AMP inducers in atopic dermatitis skin, such as the cytokines IL-1 and IL-22. 30, 43, 74 These data may explain why patients with atopic dermatitis frequently suffer from skin infection with Staph. aureus (Fig. 5 ). 187 Very recently, it has been reported that abnormal increased levels of pro-inflammatory cathelicidin peptides are present in the facial skin of patients suffering from the inflammatory skin disease rosacea. 188 In this study, evidence was provided that elevated levels of the serine pro-tease SCTE (stratum corneum tryptic enzyme, also known as kallikrein 5) in rosacea lesions contribute to this disease, because this enzyme is able to process the cathelicidin precursor hCAP18 thus generating the rosacea-specific cathelicidin peptide profile. Subcutaneous injection of these rosacea-specific cathelicidin peptides in mice induced cutaneous inflammation similar to that seen in rosacea patients. These data indicate that cathelicidin peptides may participate in the pathogenesis of rosacea and that the balance between cathelicidin and SCTE is disturbed in rosacea. 188
Wound healing
There is increasing evidence that AMPs are induced upon wounding and can promote wound healing. Investigation of the expression of hBD-2 after injury showed a marked up-regulation of hBD-2 after wounding. 189 In contrast, chronic wounds are frequently contaminated and colonized by bacteria; some studies suggest that insufficient expression of inducible antimicrobial peptides in chronic wounds compared to normal skin may promote infection. For example, decreased levels of hBD-2 were demonstrated in full-thickness burns and burn-blister fluids as well as in chronic wounds. 190, 191 These data indicate a link between burn wounds and a defect in host defense that further suggest a potential therapeutic role for AMPs in the management of burn wounds. 190 LL-37 was also shown to be up-regulated after cutaneous injury due to synthesis within epidermal ker- atinocytes and deposition from infiltrated granulocytes. 192 Using neutralizing-antibodies to LL-37, Heilborn et al. 193 demonstrated that LL-37 promotes the re-epithelialization of human skin wounds. Decreased levels of LL-37 are associated with chronic wounds such as chronic leg ulcers. 193 The authors speculated that reduction of LL-37 in chronic wounds impairs re-epithelialization and may contribute to their failure to heal. A transient cutaneous adenoviral gene therapy with the cathelicidin LL-37 proved to be effective for the treatment of burn wound infections. 194 In general, growth factors stimulate the regeneration of tissue after wounding. A recent study has shown that growth factors essential in wound healing, such as IGF-I and TGF-α, induce the expression of LL-37, hBD-3, neutrophil gelatinase-associated lipocalin (NGAL) and antileukoprotease (ALP) in human keratinocytes. 195 These findings offer an explanation for the expression of these antimicrobial peptides in wound healing and define a new host defense role for growth factors. For example, sterile wounding of human skin resulted in induced hBD-3 expression through activation of the epidermal growth factor receptor (EGFR). After skin wounding, the receptor was activated by heparin-binding EGF that was released by a metalloprotease-dependent mechanism. Activation of the EGFR generated antimicrobial concentrations of hBD-3 and increased the activity of organotypic epidermal cultures against Staph. aureus indicating that sterile wounding initiates an innate immune response that increases resistance to infection and microbial colonization. 73 Very recently, it was shown that hBD-2, hBD-3, and hBD-4, but not hBD-1, stimulated human keratinocytes to increase their gene expression and protein production of IL-6, IL-10, IP-10, monocyte chemo-attractant protein (MCP)-1, macrophage inflammatory protein (MIP)-3α, and RANTES. 196 In addition, hBDs elicited intracellular Ca 2+ mobilization, increased keratinocyte migration and proliferation, and induced phosphorylation of EGFR and signal transducer and activator of transcription (STAT)-1 and STAT-3, which are intracellular signaling molecules involved in keratinocyte migration and proliferation. These data provide evidence that human antimicrobial peptides can participate in wound healing by stimulating cytokine/chemokine production and promoting keratinocyte migration and proliferation.
In a recent publication, the role of S100A7 in human wound exudate and granulation tissue was investigated. 115 Immunohistological studies suggest that S100A7 is produced by keratinocytes surrounding the wound and is released into the wound exudate.
AMP deficiency in leukocytes
Evidence for an important functional role of neutrophil α-defensins in killing of phagocytosed microbes can be seen in patients suffering from specific granule deficiency (SGD). 197 The neutrophilic granulocytes from these patients lack α-defensins (HNPs). SGD patients suffer from frequent and severe bacterial infections, which suggests that the deficiency of α-defensins may contribute to the clinical manifestations of these disorders. 197 The neutrophilic granulocytes of patients with Kostmann syndrome (or severe congenital neutropenia) fail to reach a mature and functional state and, therefore, patients often suffer from infections beginning in the first month of life. Human granulocyte colony-stimulating factor (G-CSF) can greatly improve both life quality and the life span of patients with Kostmann syndrome, but problems with infections persist, especially regarding chronic gingivitis and periodontitis. 198 It has been shown that neutrophilic granulocytes from patients with Kostmann syndrome have reduced concentrations of α-defensins HNPs 1-3 and they are deficient in LL- 37. 199 In addition, LL-37 is absent in the saliva of these patients. These observations suggest that a deficiency of AMPs in Kostmann syndrome causes a predisposition to infections. 199 Recently, an important role of LL-37 in Mycobacterium tuberculosis infection has been reported. 200 Activation of the Toll-like receptor heterodimer TLR2/1 in human monocytes induces the expression of the vitamin D receptor (VDR) as well as the 25-hydroxyvitamin-D 3 -1α-hydroxylase (Cyp27B1; cytochrome P450 subfamily XXVIIB polypeptide 1), the enzyme that catalyzes conversion of inactive 25-hydroxyvitamin D 3 hormone into the active 1,25-dihydroxyvitamin D 3 . 1,25-Dihydroxyvitamin D 3 induces downstream targets of VDR such as LL-37 which is able to kill M. tuberculosis. Interestingly, sera from African-American individuals had low 25-hydroxyvitamin D and they were inefficient in induction of LL-37 expression. Supplementation of the African-American serum with 25hydroxyvitamin D 3 hormone to a physiological range restored TLR induction of LL-37 mRNA. These data provide an explanation for the action of vitamin D as a key link between TLR activation and antibacterial responses in innate immunity and provide a molecular mechanism for the increased susceptibility of African-American individuals to tuberculosis. 200 However, the authors of this study stated that they do not imply that this is the only antimicrobial mechanism available to human macrophages. This innate immune pathway is likely complemented by T-cell-dependent adaptive immune mechanisms, which include macrophage activation by cytokines and the release of granulysin. 200, 201 
INTERACTION WITH ENDOTOXIN
Binding to LPS seems to be a prerequisite of many AMPs for specific interactions with the bacterial mem-brane which finally lead to bacterial killing. 152 Differences in the activity of cationic AMPs such as defensins and cathelicidins against various sensitive and resistant Gram-negative bacteria can be explained solely by variations in the chemical structure of LPS (e.g. in the composition of the sugar head group). Reduction of the net negative charge of LPS entails reduced interaction with AMPs and increased bacterial resistance. 202 Many AMPs have been shown to bind to endotoxin and neutralize its toxic effects. One potent endotoxin-binding human AMPs is bactericidal/permeability-increasing protein (BPI). [203] [204] [205] BPI is a 55-kDa constituent of the primary granules of neutrophilic granulocytes and has various anti-infective properties -bacterial membrane permeabilization and potent antibacterial activity against Gram-negative bacteria, high affinity for LPS and suppression of LPS bioactivity, and opsonic activity toward Gram-negative bacteria. 206, 207 The antibacterial activity of BPI against Gram-negative bacteria as well as its potent endotoxin neutralizing effect makes it an attractive candidate in the treatment of sepsis. A modified recombinant fragment of BPI containing an antimicrobial and endotoxin-neutralising moiety was tested in several clinical trials for adjunctive treatment of children with severe meningococcemia as outlined below. α-Defensins are also able to exhibit anti-endotoxic effects but they are approximately 1000-fold less potent than BPI. 205 Another AMP with endotoxin-neutralizing activity is the cathelicidin LL-37. 208 The anti-endotoxic effect of LL-37 may contribute to its capacity to protect rats against lethal sepsis caused by Gram-negative bacteria and it can be speculated that LL-37 may become an important future consideration for the treatment of sepsis. 209 Recently, the histones have been identified as a new class of endotoxin-binding molecules. 210
POTENTIAL AS DRUGS
AMPs have a broad spectrum of antimicrobial activity in vitro against many potential pathogenic microbes including multiresistant bacteria, which suggests that they may be useful as a novel class of antibiotics to fend off infections. However, although the number of reports about the use of animal-derived AMPs in clinical trials is increasing, 211 clinical studies evaluating the usefulness of human AMPs are still rare and only a few human AMPs have been considered as potential anti-infective therapeutic agents. As mentioned above, a modified recombinant fragment of BPI (rBPI21) containing an antimicrobial and endotoxin-neutralizing moiety was tested in several clinical trials for adjunctive treatment of children with severe meningococcemia. Data from these trials indicated that rBPI21 is beneficial in decreasing the number of complications associated with meningo-coccal disease although the data are not yet sufficient to lead to an approved clinical application. 212, 213 Nonetheless, many studies suggested that BPI could act in vivo and help protect against Gram-negative bacterial infection and LPS-induced inflammation. 214, 215 Cationic peptides based on histatins have therapeutic potential because they showed excellent in vitro activity against C. albicans and common bacteria. 153 P-113, a 12 amino acid histatin-based peptide, was evaluated in a mouth rinse formulation for safety and efficacy in a Phase II multicenter clinical study. The results of this study revealed that P-113 mouth rinse is safe and reduces the development of gingival bleeding, gingivitis and plaque formation. 216 Several important issues have to be addressed when considering human AMPs as novel therapeutic agents. For example, does overuse of an AMP provoke the spread of bacteria with increasing resistance against human AMPs? One could argue that acquisition of complete resistance is unlikely because AMPs have been protecting our ancestors for millions of years and are still active against many bacteria. 148 This phenomenon is surprising because AMPs are genetically encoded and the mutation rate in bacteria is much greater than the rate of adaptive mutations in mammals. This suggests that the mutations that could render resistance have already occurred and, therefore, the use of human AMPs would not provoke a new selective pressure. However, it has been shown that some bacteria have developed various strategies to decrease their susceptibility to AMPs. 217 Most AMPs have a cationic charge because this favors the affinity to the negatively charged bacterial surface. Some bacteria developed a simple strategy to decrease the initial interaction with AMPs by reducing the net charge of the cell envelope by modifying teichoic acid with d-alanine residues. 218, 219 Other strategies to reduce the surface charge include acylation of lipid A or modification of the membrane lipid phosphatidylglycerol with l-lysine. 220, 221 Through these modifications of their cell surface, bacteria have acquired some protection against the killing activities of cationic AMPs. However, these modifications do not result in complete resistance to AMPs and even bacteria capable of using this strategy remain susceptible to high concentrations of AMPs. 217 An interesting possibility is that the cationic properties of AMPs have increased during evolution in order to maintain their activity against bacteria that have decreased their anionic envelope charge. Other strategies to reduce bacterial susceptibility to AMPs comprise elimination of AMPs through efflux pumps and degradation of AMPs through bacterial proteases. 217 Another major problem may be the occurrence of toxic side-effects when applying high doses of AMPs. As many AMPs display various immunomodulatory activities besides their antimicrobial activity, the admin-istration of high doses of AMPs in their native form may have some undesirable side-effects. Indeed, in a mouse model, it has been shown that an intratracheal instillation of defensins causes acute lung inflammation and dysfunction. 222 An alternative approach to the direct application of AMPs may be the specific induction of AMPs synthesis. The finding that some bacteria, including probiotic bacteria, 51 have a high capacity to induce AMPs in vitro and that other bacteria release substances that induce psoriasin in vivo in the absence of inflammation 112 encourages the search for naturally occurring compounds that solely induce AMPs without inducing inflammatory reactions. These would, when topically applied, induce AMPs locally in the appropriate place and within the appropriate cellular compartment. Such compounds could initiate epithelial induction of AMPs and would be ideal 'immune-stimulants' that could be used for artificial stimulation of AMPs synthesis in various epithelia. Consequently, one would expect an increased resistance to infection in such epithelia. In line with this hypothesis, a recent study reported that oral butyrate treatment of rabbits induced the expression of the cathelicidin CAP-18 (the rabbit homolog to LL-37) in the colonic epithelium and promoted elimination of Shigella spp. 137
CONCLUSIONS AND FUTURE PROSPECTS
Since Alexander Fleming's description of the antibacterial activity of lysozyme, great progress has been made in the characterization of human AMPs. The high number of human AMPs and their potent antimicrobial activity suggest that these proteins may play a major part in innate immunity. The constitutive as well as inducible production of AMPs offers a rapid response against invading micro-organisms, and it seems possible that AMPs are crucial for human survival. However, future research is necessary to understand the role of AMPs in protecting from infection. Most research on AMPs was done in vitro and it is a great future challenge to understand the in vivo role of AMPs. The knockout mouse of the human cathelicidin LL-37 ortholog CRAMPs has been extensively used to study the role of cathelicidins in vivo, and the human defensin-5 (HD-5) transgenic mice provided insight into the in vivo role of HD-5. Therefore, much will be learned by using mice that are deficient in AMP expression or that overexpress human AMPs.
There is ample evidence that a deficiency or inactivation of AMPs may be related to the pathogenesis of distinct infectious and inflammatory diseases. A better understanding of the role of AMPs in such diseases would probably help the development of novel therapeutic strategies based on the modulation of AMP expres-sion or direct application of AMPs. An intriguing possibility is that the artificial induction or direct application of AMPs may have beneficial therapeutic effects for the treatment of infectious diseases. The high activity of many AMPs against multiresistant bacteria makes them attractive candidates for novel therapeutic agents to treat infectious diseases where conventional antibiotics have failed to kill these multiresistant strains. The discovery of AMPs provides an opportunity to develop improved antimicrobial therapies based on 'natural antibiotics' designed during evolution to fend off infection effectively. However, the problem of the development of AMP resistance by pathogens must be critically addressed before AMPs can be used in clinical practice.
